e-therapeutics plc (LON:ETX – Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 10.39 ($0.14) and traded as low as GBX 9 ($0.12). e-therapeutics shares last traded at GBX 9 ($0.12), with a volume of 2,518,125 shares changing hands.
e-therapeutics Price Performance
The company has a quick ratio of 20.13, a current ratio of 22.20 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average is GBX 9 and its two-hundred day moving average is GBX 10.39. The company has a market capitalization of £52.59 million, a P/E ratio of -450.00 and a beta of 0.46.
e-therapeutics Company Profile
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
Recommended Stories
- Five stocks we like better than e-therapeutics
- 3 Warren Buffett Stocks to Buy Now
- The Average 401k Balance by Age Explained
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Market Cap Calculator: How to Calculate Market Cap
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.